141 related articles for article (PubMed ID: 7492599)
1. Hydroxyquinones are competitive non-peptide inhibitors of HIV-1 proteinase.
Brinkworth RI; Fairlie DP
Biochim Biophys Acta; 1995 Nov; 1253(1):5-8. PubMed ID: 7492599
[TBL] [Abstract][Full Text] [Related]
2. Flavones are inhibitors of HIV-1 proteinase.
Brinkworth RI; Stoermer MJ; Fairlie DP
Biochem Biophys Res Commun; 1992 Oct; 188(2):631-7. PubMed ID: 1445308
[TBL] [Abstract][Full Text] [Related]
3. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezácová P; Brynda J; Pokorná J; Plesek J; Grüner B; Grantz Sasková K; Václavíková J; Král V; Konvalinka J
J Med Chem; 2008 Aug; 51(15):4839-43. PubMed ID: 18598016
[TBL] [Abstract][Full Text] [Related]
4. Non-peptidic anti-AIDS agents: inhibition of HIV-1 proteinase by disulfonates.
Brinkworth RI; Fairlie DP
Biochem Biophys Res Commun; 1992 Oct; 188(2):624-30. PubMed ID: 1445307
[TBL] [Abstract][Full Text] [Related]
5. Design of symmetry-based, peptidomimetic inhibitors of human immunodeficiency virus protease.
Kempf DJ
Methods Enzymol; 1994; 241():334-54. PubMed ID: 7854187
[No Abstract] [Full Text] [Related]
6. A quantitative structure-activity relationship study on some sulfolanes and arylthiomethanes acting as HIV-1 protease inhibitors.
Gupta SP; Babu MS; Sowmya S
Bioorg Med Chem; 1998 Nov; 6(11):2185-92. PubMed ID: 9881109
[TBL] [Abstract][Full Text] [Related]
7. Identifying the molecular mechanics and binding dynamics characteristics of potent inhibitors to HIV-1 protease.
Li D; Liu MS; Ji B; Hwang KC; Huang Y
Chem Biol Drug Des; 2012 Sep; 80(3):440-54. PubMed ID: 22621379
[TBL] [Abstract][Full Text] [Related]
8. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Muzammil S; Ross P; Freire E
Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
[TBL] [Abstract][Full Text] [Related]
9. Enamino-oxindole HIV protease inhibitors.
Eissenstat M; Guerassina T; Gulnik S; Afonina E; Silva AM; Ludtke D; Yokoe H; Yu B; Erickson J
Bioorg Med Chem Lett; 2012 Aug; 22(15):5078-83. PubMed ID: 22749283
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors.
Thaisrivongs S; Tomich PK; Watenpaugh KD; Chong KT; Howe WJ; Yang CP; Strohbach JW; Turner SR; McGrath JP; Bohanon MJ
J Med Chem; 1994 Sep; 37(20):3200-4. PubMed ID: 7932546
[No Abstract] [Full Text] [Related]
11. Inhibition of wild-type and mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides.
Hanlon MH; Porter DJ; Furfine ES; Spaltenstein A; Carter HL; Danger D; Shu AY; Kaldor IW; Miller JF; Samano VA
Biochemistry; 2004 Nov; 43(45):14500-7. PubMed ID: 15533054
[TBL] [Abstract][Full Text] [Related]
12. A modular approach to HIV-1 proteinase inhibitor design.
Uhlíková T; Konvalinka J; Pichová I; Soucek M; Kräusslich HG; Vondrásek J
Biochem Biophys Res Commun; 1996 May; 222(1):38-43. PubMed ID: 8630071
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.
Skulnick HI; Johnson PD; Howe WJ; Tomich PK; Chong KT; Watenpaugh KD; Janakiraman MN; Dolak LA; McGrath JP; Lynn JC
J Med Chem; 1995 Dec; 38(26):4968-71. PubMed ID: 8544171
[No Abstract] [Full Text] [Related]
14. New active HIV-1 protease inhibitors derived from 3-hexanol: conformation study of the free inhibitors in crystalline state and in complex with the enzyme.
Ziółkowska NE; Bujacz A; Randad RS; Erickson JW; Skálová T; Hašek J; Bujacz G
Chem Biol Drug Des; 2012 May; 79(5):798-809. PubMed ID: 22296826
[TBL] [Abstract][Full Text] [Related]
15. Rationale for more diverse inhibitors in competition with substrates in HIV-1 protease.
Ozer N; Schiffer CA; Haliloglu T
Biophys J; 2010 Sep; 99(5):1650-9. PubMed ID: 20816079
[TBL] [Abstract][Full Text] [Related]
16. Structure of a non-peptide inhibitor complexed with HIV-1 protease. Developing a cycle of structure-based drug design.
Rutenber E; Fauman EB; Keenan RJ; Fong S; Furth PS; Ortiz de Montellano PR; Meng E; Kuntz ID; DeCamp DL; Salto R
J Biol Chem; 1993 Jul; 268(21):15343-6. PubMed ID: 8340363
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands.
Qiu X; Zhao GD; Tang LQ; Liu ZP
Bioorg Med Chem Lett; 2014 Jun; 24(11):2465-8. PubMed ID: 24767846
[TBL] [Abstract][Full Text] [Related]
18. Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.
Ghosh AK; Takayama J; Kassekert LA; Ella-Menye JR; Yashchuk S; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
Bioorg Med Chem Lett; 2015 Nov; 25(21):4903-4909. PubMed ID: 26096678
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease.
Mazumder A; Wang S; Neamati N; Nicklaus M; Sunder S; Chen J; Milne GW; Rice WG; Burke TR; Pommier Y
J Med Chem; 1996 Jun; 39(13):2472-81. PubMed ID: 8691444
[TBL] [Abstract][Full Text] [Related]
20. Peptide aldehydes as inhibitors of HIV protease.
Sarubbi E; Seneci PF; Angelastro MR; Peet NP; Denaro M; Islam K
FEBS Lett; 1993 Mar; 319(3):253-6. PubMed ID: 8458418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
